Background: Cardiac metastases from thyroid cancers are uncommon with a poor prognosis. There is a lack of long-term follow-up studies. Cases: We report 2 cases of cardiac metastasis from medullary thyroid cancer (MTC). Both patients presented limited metastatic disease apart from a cardiac metastasis. The initial diagnosis was challenging and was facilitated by functional imaging with an immuno-PET-CT using an anti-CEA bispecific antibody and a ⁶⁸Ga-labeled peptide. Both patients were treated with the multitarget kinase inhibitor vandetanib with prolonged stability. The first patient was alive at the last follow-up, 14 years after the diagnosis of cardiac metastasis. The second patient required surgical excision of the cardiac mass because of disease progression under vandetanib. Conclusion: These cases illustrate long-term survival and effectiveness of clinical management of 2 patients who developed cardiac metastases from MTC, in the current era of personalized medicine with targeted therapy.
Eur Thyroid J

中文翻译：

---

甲状腺髓样癌的心脏转移在凡德他尼下长期存活

背景：甲状腺癌的心脏转移并不常见，预后较差。缺乏长期随访研究。病例：我们报告了 2 例甲状腺髓样癌 (MTC) 的心脏转移病例。除心脏转移外，两名患者均表现出有限的转移性疾病。初步诊断具有挑战性，并通过使用抗 CEA 双特异性抗体和⁶⁸Ga标记的肽。两名患者都接受了多靶点激酶抑制剂凡德他尼的治疗，具有延长的稳定性。在诊断心脏转移14年后，第一个患者在最后一次随访中还活着。第二名患者需要手术切除心脏肿块，因为在凡德他尼下疾病进展。结论：这些病例说明了在当前个性化医疗和靶向治疗时代，2 例 MTC 心脏转移患者的长期生存和临床管理的有效性。
欧洲甲状腺杂志